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Abstract: Metastasis Associated Lung Adenocarcinoma Transcript-1 (MALAT1) is implicated in
regulating the inflammatory response and in the pathology of several chronic inflammatory diseases,
including osteoarthritis (OA). The purpose of this study was to examine the relationship between
OA subchondral bone expression of MALAT1 with parameters of joint health and biomarkers of
joint inflammation, and to determine its functional role in human OA osteoblasts. Subchondral
bone and blood were collected from hip and knee OA patients (n = 17) and bone only from neck of
femur fracture patients (n = 6) undergoing joint replacement surgery. Cytokines were determined by
multiplex assays and ELISA, and gene expression by qPCR. MALAT1 loss of function was performed
in OA patient osteoblasts using locked nucleic acids. The osteoblast transcriptome was analysed
by RNASeq and pathway analysis. Bone expression of MALAT1 positively correlated to serum
DKK1 and galectin-1 concentrations, and in OA patient osteoblasts was induced in response to IL-1β
stimulation. Osteoblasts depleted of MALAT1 exhibited differential expression (>1.5 fold change) of
155 genes, including PTGS2. Both basal and IL-1β-mediated PGE2 secretion was greater in MALAT1
depleted osteoblasts. The induction of MALAT1 in human OA osteoblasts upon inflammatory
challenge and its modulation of PGE2 production suggests that MALAT1 may play a role in regulating
inflammation in OA subchondral bone.
Keywords: osteoarthritis; osteoblasts; MALAT1; long non-coding RNA
1. Introduction
Osteoarthritis (OA) is a degenerative joint disease and a leading cause of pain and
disability for which there are currently no approved pharmacological disease modifying
therapeutics [1]. Current OA treatment is limited to generic analgesics that have limited effi-
cacy, physical therapy and ultimately joint replacement surgery [2,3]. Non-pharmacological
therapeutic strategies such as platelet rich plasma and mesenchymal stem cells, aimed at
promoting cartilage repair, hold promise but require further clinical studies to confirm
efficacy and safety [4]. There is therefore a high unmet healthcare need to better understand
the pathophysiology of OA and to develop an effective disease modifying therapeutic [5].
Importantly, despite initially considered to be a disease solely of the articular cartilage, it
is now widely accepted that OA is a disease that encompasses the whole joint, including
underlying subchondral bone tissue [2]. Pathological changes to OA subchondral bone
tissue, characterised by trabecular thickening [6], abnormal type I Collagen production [7,8]
and the formation of osteophytes, occurs early in the disease course of OA [9] and involves
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changes to the osteoblast phenotype [10]. Furthermore, in animals that are prone to devel-
oping OA trabecular thickening occurs prior to cartilage degeneration [11] and thus it has
been suggested that this alteration to the bone architecture may pathologically alter the
loading biomechanics, thus promoting cartilage degeneration [12]. Therefore, identifying
novel regulators that mediate the functional phenotype of osteoblasts, the cells which
regulate bone remodelling, may identify new opportunities for the development of new
OA therapeutics that target the bone.
Recently, long non-coding RNAs (lncRNAs) have emerged as novel epigenetic regula-
tors of gene transcription [13,14] and of mediating several cellular processes including cellu-
lar proliferation, cell cycle control, apoptosis and the innate inflammatory response [15–18].
As such, lncRNAs have now been implicated in the pathology of several chronic inflam-
matory diseases [19,20], including OA [21]. Indeed, lncRNAs have been identified that
are differentially expressed in OA diseased cartilage and which mediate the IL-1β inflam-
matory response in OA chondrocytes [21,22]. Furthermore, we recently reported that
Metastasis Associated Lung Adenocarcinoma Transcript-1 (MALAT1) lncRNA modulates
the inflammatory phenotype of synovial fibroblasts in the OA synovial joint lining by me-
diating the production of CXCL8 [23]. However, importantly, MALAT1 lncRNA has now
emerged as a central mediator of osteoblast function and bone homeostasis. Expression
of MALAT1 is reported to be greater in the bone tissue of patients who exhibit aseptic
loosening following a hip replacement [24] and its upregulation has been implicated in
lumber intervertebral disc degeneration [25]. In vitro, knockdown of MALAT1 has been
demonstrated to inhibit the proliferation of the human osteoblast cell line hFOB 1.19 [24],
and MALAT1 sponging of the microRNA miR-30 has been shown to promote the osteoblast
differentiation of mesenchymal stem cells by inducing RUNX2 expression [26]. Further-
more, MALAT1 is associated with abnormal osteogenic and adipogenic differentiation of
BMSCs in the patients with osteonecrosis of the femoral head [27].
These data suggest that MALAT1 could play a key role in the pathological changes
that occur in OA diseased bone. However, currently the expression and functional role of
MALAT1 in OA subchondral bone has not been reported. Therefore, the aim of this study
was to profile the expression of MALAT1 in the subchondral bone tissue of patients with
either knee or hip OA and its relationship to parameters of joint damage and to examine
the functional role of MALAT1 in OA patient primary osteoblasts.
2. Materials and Methods
2.1. Patient Recruitment
Following ethical approval (UK NRES 16/SS/0172 & NRES 14/ES/1044 approved
on 31 October 2016 and 12 August 2014, respectively), subchondral bone tissue and blood
was collected from a total of 17 patients (9 males, 8 females) with end-stage OA comprising
of 9 patients with hip OA and 8 patients with knee OA and from neck of femur fracture
(NOF#) patients without OA (n = 6), who were undergoing surgery at Russell’s Hall
Hospital (Dudley, UK) or the Royal Orthopaedic Hospital (Birmingham UK). OA patient
characteristics are detailed in Table 1. All participants demonstrating secondary causes
of OA, such as avascular necrosis, Perthes disease, developmental dysplasia, previous
acetabular or femoral neck fractures and slipped upper femoral epiphysis, were excluded
from the study. Informed consent was obtained from all subjects involved in the study.
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Table 1. OA patient characteristics.
All OA Patients Knee OA Patients Hip OA Patients
Age (years) 65 ± 2.2 67 ± 3.1 63.2 ± 3.2
Gender (m:f) 9:7 4:4 5:3
Height (cm) 167.2 ± 3.2 164.8 ± 5.4 169.4 ± 3.8
Weight (Kg) 82.4 ± 4.2 84.2 ± 7.9 80.8 ± 4.3
BMI (kg/m2) 29.7 ± 1.6 31.1 ± 2.7 28.4 ± 1.9
% Fat 34.8 ± 2.4 35.0 ± 5.1 34.8 ± 2.3
WHR 1 0.92 ± 0.02 0.93 ± 0.03 0.91 ± 0.03
KL Grade 4 (3.5–4) 4 (3.25–4) 4 (3.5–4)
1 WHR = Ratio of waist to hip circumference. All values represent mean ± SEM, except KL grade which is shown
as median (25th–75th percentile).
2.2. Isolation and Culture of Primary Osteoblasts
Primary OA osteoblasts were cultured from OA subchondral bone tissue. The bone
was cut into small pieces approximately 2 mm3 and washed 3 times in 30 mL of com-
plete osteoblast culture media (DMEM, 10% FBS, 100 Units/mL Penicillin, 100 ug/mL
Streptomycin, 1% Non-essential amino acids, L-glutamine 2 mM, ascorbic acid 50 ug/mL,
Dexamethasone 10 nM, and β-glycerophosphate 2 mM) to remove excess fat. The bone
chips were then placed in a T75 flasks with fresh culture media and incubated in at 37 ◦C
in a humidified atmosphere containing 5% CO2. The media was changed every 3–4 days,
and the chips were removed after 7–14 days when the osteoblasts outgrowth occurred.
2.3. Analysis of Serum Cytokines
The serum concentration of 24 cytokines were determined using Luminex multiplex
platform (Luminex R&D systems) according to the manufacturer’s instructions, having
been diluted to 1:2 in assay buffer.
2.4. MALAT1 Functional Studies in Human OA Osteoblasts
In vitro loss of function studies were performed using lipofectamine 3000 (Qiagen,
Manchester, UK) to transfect primary osteoblasts with two different Locked nucleic acids
(LNAs) targeting MALAT1 or with a control (NC) LNA. To determine the effect of MALAT1
knockdown on the OA osteoblast transcriptome, total RNA was extracted (RNeasy columns,
Qiagen Manchester UK) 24 h following transfection with LNAs. RNA integrity (RIN) was
evaluated (Agilent Bioanalyser, Cheshire UK) with a RIN of >7 deemed of sufficient quality
for RNA sequencing analysis using the QuantSeq 3′ kit (Lexogen, Vienna, Austria). The
sequenced reads were mapped to the hg38 reference human genome using Star Aligner
version 2.5.2b [28]. Differential gene expression analysis and log2 fold changes were
computed using DESeq2 version 1.26.0 [29].
The effect of MALAT1 knockdown on the production of PGE2 and osteoprotegrin
(OPG) was determined by ELISA according to the manufacturer’s instructions (RnD sys-
tems, Oxford, UK). Alkaline phosphatase (ALP) activity was quantified in osteoblast lysates
prepared in RIPA buffer diluted 1:5 with 1 mM MgCl2. In brief, diluted osteoblast lysates
were combined with ALP substrate (Sigma, Gillingham, UK) and incubated at 37 ◦C for
15 min. The reaction was stopped with the addition of 0.1 N NaOH and absorbance read at
405 nm on a microplate reader. The degree of osteoblast mineralisation was quantified by
staining of mineralised nodules using an alizarin red solution (0.5% Alizarin Red in 1%
ammonia hydroxide at pH 4.5; Sigma, Gillingham, UK). Following 10 min incubation at
room temperature, cells were washed with PBS to remove excess stain, and then incubated
in 10% cetyl pyridinium chloride (Sigma, Gillingham, UK) for 10 min. The supernatant
was then collected, diluted 1:10 with the 10% cetyl pyridinium chloride and absorbance
read at OD550 nm on a microplate reader.
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2.5. Pathway Analysis
Pathway analysis was performed using the software Ingenuity Pathway Analysis
(IPA; www.ingenuity.com, accessed on 31 January 2020). Differentially expressed genes
(fold change of ± >1.5, p < 0.05) were analysed using a core functional analysis to identify
significant canonical pathways and cellular processes.
2.6. Statistical Analysis
All statistics were performed using Graph Pad Prism 9.0. ANOVA followed by post
hoc analysis of Bonferroni was used to test statistical significance where appropriate.
Pearson correlations were performed to test the strength of association between two
variables. p-value < 0.05 was considered as significant.
3. Results
3.1. Expression of MALAT1 in OA Subchondral Bone and Relationship to Patient Characteristics
and OA Disease Severity
MALAT1 was highly expressed in OA subchondral bone tissue, with on average
greater expression in hip OA compared to non-OA hip (NOF#). However, this did not
reach significance and there was no significant difference in expression between patients
with knee OA and those with hip OA (Figure 1A). Furthermore, although on average there
was greater MALAT1 expression in OA patients with greater disease severity (KL4 and
joint space < 1 mm), compared to those patients with KL grade 3 and joint space > 1 mm,
there was no significant relationship between MALAT1 expression and disease severity
(Figure 1B; Supplementary Table S1).
Next, we examined whether the subchondral bone expression of MALAT1 was related
to biomarkers of inflammation by measuring the concentration of a panel of 22 cytokines
in OA patient serum by Luminex. There were significant positive correlations between
MALAT1 expression and the serum concentration of both the Wnt pathway inhibitor DKK1
(r2 = 0.3, p = 0.04) and galectin-1 (r2 = 0.44, p = 0.009) (Figure 1C; Table 2). However,
it should be noted that these findings were not significant upon correcting for multiple
comparisons (FDR), and therefore a type I error cannot be ruled out.
Table 2. Relationship between MALAT1 subchondral bone expression and the concentration of
cytokines in OA patient serum.
Concentration a r2 p-Value
Visfatin 2979 ± 355 0.11 0.23
Resistin 15441 ± 1394 0.17 0.18
Leptin 18365 ± 5865 0.03 0.55
Adiponectin 10640 ± 2081 b <0.01 0.94
Chemerin 6920 ± 937 <0.01 0.67
Dkk1 3.7 ± 0.3 b 0.3 0.04
Galectin1 41 ± 3 b 0.44 0.009
Eotaxin 170 ± 44 0.15 0.16
Amphiregulin 570 ± 54 0.24 0.07
Aggrecan 183 ± 54 0.10 0.28
FABP4 47.4 ± 15.2 b 0.04 0.48
Serpin E1 131 ± 19 b 0.02 0.63
IP10 32.3 ± 5.9 0.03 0.56
MIP1a 400 ± 76 0.06 0.39
MIP1b 188 ± 31 0.01 0.74
MCP1 398 ± 38 <0.01 0.94
MIP3a 37.3 ± 6.8 0.07 0.38
IL-1β 17.6 ± 3.1 0.007 0.78
IL6 10.9 ± 4.1 0.05 0.55
IL7 3.4 ± 0.3 0.09 0.29
IL10 4.5 ± 0.3 0.01 0.69
IL15 5.3 ± 1.6 0.02 0.66
TNF-α 4.3 ± 0.3 0.08 0.32
Gp130 94 ± 7.1 b 0.02 0.63
a Concentration of cytokines in pg/mL ± SEM. Except b, concentration of cytokines in ng/mL.
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Figure 1. Expression of MALAT1 in subchondral bone and OA osteoblasts. (A) Relative expression of
MALAT1 in the subchondral bone tissue of end-stage hip OA patients (n = 9) compared to end-stage
knee OA patients (n = 8) and non-OA neck of femur fracture (NOF#) patients (n = 6). MALAT1
expression was determined by qPCR and normalised to 18S. Bars represent mean expression ± SEM.
(B) Relative expression of MALAT1 in the subchondral bone tissue between OA patients with more
severe radiographic signs of OA (n = 13) with joint space < 1 mm and KL grade 4, compared to
those with less severe joint damage (n = 4) with joint space > 1 mm and KL grade 3. (C) Correlation
between subchondral bone expression of MALAT1 and the serum concentration of Galectin 1 (ng/mL)
and DKK1 (ng/mL) in OA patients (n = 17). (D) Effect of IL-1β stimulation (1 ng/mL) upon the
expression of IL-6 and MALAT1 in primary OA osteoblasts at 6 h and 24 h. * = p < 0.05, compared to
non-stimulated control.
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3.2. MALAT Expression in OA Osteoblasts Is Induced by Inflammatory Challenge
Next, using an in vitro model of primary OA patient osteoblasts, we examined whether
the expression of MALAT1 was induced upon an inflammatory challenge. To this end,
primary osteoblasts from n = 3 OA patients were stimulated for either 6 h or 24 h with IL-1β
(1 ng/mL), and the expression of IL-6 and MALAT1 determined by qPCR. As expected,
stimulation of osteoblasts with IL-1β induced a significant increase in the expression of the
pro-inflammatory cytokine IL-6 within 24 h (23-fold, p < 0.05), compared to non-stimulated
control. Similarly, osteoblasts stimulated with IL-1β for 24 h exhibited significant in-
crease in the expression of MALAT1 (4-fold, p < 0.05), compared to non-stimulated control
(Figure 1D).
3.3. The Effect of MALAT1 Knockdown on the OA Osteoblast Transcriptome
To examine the functional role of MALAT1 in OA subchondral osteoblasts we next con-
ducted loss of function studies by performing targeted knockdown of MALAT1 expression
using locked nucleic acids (LNAs) and examined the resulting osteoblast transcriptome by
RNA sequencing. Primary OA osteoblasts (n = 3 OA patients) were transfected with either
a non-targeting control LNA or one of two LNA duplexes targeting MALAT1. Following
24 h transfection, LNAs targeting MALAT1 induced knockdown of between 60–90% in
the expression of MALAT1, compared to the control LNA (Figure 2A). RNAseq identi-
fied 155 transcripts (82 upregulated and 73 downregulated), which were differentially
expressed (>1.5-fold change, p-value ≤ 0.05) in osteoblasts transfected with the MALAT1
LNAs, compared to LNA control transfected cells. Of the upregulated transcripts, 80 were
protein coding genes (including PTGS2) and 2 were antisense lncRNAs. Of the down-
regulated transcripts, 66 were protein-coding genes and 7 were lncRNAs, which comprised
of 2 lincRNAs, 3 antisense, 1 sense intronic lncRNA and 1 pseudogene (Figure 2B,C,
Supplementary Tables S2 and S3).
To understand the functional effect of this MALAT1 mediated change in osteoblast
transcriptome we next analysed the 155 differentially expressed genes by bioinformatic
pathway analysis (Ingenuity Pathway Analysis) to identify significantly affected canonical
pathways and cellular processes. The most significant canonical pathways affected included
phosphatidylcholine biosynthesis, fMLP signalling in neutrophils, NAD biosynthesis,
eicosanoid biosynthesis and prostanoid biosynthesis. The significantly affected cellular
processes included cell–cell signalling, DNA replication, cellular growth and proliferation
and cellular development (Figure 2D).
3.4. Modulation of MALAT1 Expression in Osteoblasts Induced PGE2 Secretion but Did Not
Impair Osteoblast OPG Secretion or Their Innate Ability to Mineralise
Given the finding that knockdown of MALAT1 induced the expression of PTGS2, we
next examined if this was reflected in a greater production of the prostaglandin PGE2, a
purported mediator of pain and inflammation in OA. To this end, OA osteoblasts were
transfected with either a control LNA or one of two MALAT1 LNAs for 24 h. Cells were
then either stimulated for 24 h with IL-1β (1 ng/mL) or left unstimulated and secretion
of PGE2 quantified by ELISA. MALAT1 knockdown was confirmed by qPCR (Figure 3A).
Compared to LNA control, cells depleted of MALAT1 exhibited greater basal and IL-1β
induced PGE2 production (2-fold, p < 0.05) (Figure 3B).
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Figure 2. The effect of MALAT1 knockdown on the OA osteoblast transcriptome. (A) Knockdown of MALAT1 expression
in primary OA osteoblasts. Osteoblasts were transfected with either a non-targeting control LNA (NC) or one of two
LNAs targeting MALAT1, M1(1) and M1(2). Expression of MALAT1 was determined by qPCR 24 h after transfection
and normalised to 18S. (B) Heatmap of differentially expressed genes (>1.5-fold, p < 0.05) as determined by RNAseq
(Quantseq) following 24 h LNA-mediated MALAT1 knockdown. (C) Table of the most upregulated and down-regulated
genes following MALAT1 knockdown, with Venn diagram illustrating the total numbers of genes differentially expressed
(>1.5-fold, p < 0.05) with each of the MALAT1 LNAs. Values represent the mean fold change between control LNA and
MALAT1(1) LNA and between control LNA and MALAT1(2) LNA. (D) Top canonical pathways and cellular processes as
determined by Ingenuity Pathway Analysis of the differentially expressed genes (fold change > 1.5, p < 0.05) following
MALAT1 knockdown, with logP values representing the significance between the pathway/process and the gene dataset
and n representing the numbers of genes within the dataset aligned to the pathway/process.
Next, we investigated whether chronic loss of function of MALAT1 would affect
the innate function of osteoblasts with regard to bone remodelling by determining OPG
production, alkaline phosphatase activity and osteoblast mineralisation. To this end, OA
osteoblasts were transfected with either a control LNA or a MALAT1 LNA twice per week
for a period of 3 weeks. During the 3-week time course, supernatants were collected
to analyse OPG production by ELISA and cells lysed to measure alkaline phosphatase
activity. At the end of the 3 weeks, cells were stained with alizarin red to quantify min-
eralisation. Twice weekly transfection with LNA maintained the significant knockdown
in MALAT1 expression of between 65–85% (Figure 3C). Production of OPG from both
control and MALAT1 LNA transfected cells increased throughout the 3-week time course.
However, there was no significant difference in either the rate of OPG production or in
the total amount secreted (Figure 3D). Furthermore, there was no significant difference in
either alkaline phosphatase activity (Figure 3E) or the degree of osteoblast mineralisation
(Figure 3F) between MALAT1 depleted osteoblasts and control cells.
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Figure 3. The effect of MALAT1 knockdown on the function of OA osteoblasts. (A) Knockdown of MALAT1 in OA
osteoblasts (n = 6) following 24 h transfection with LNAs targeting MALAT1 (M1(1) and M1(2)), compared to LNA control
(NC). (B) Effect of MALAT1 knockdown on 24 h basal and IL-1β mediated production of PGE2, as measured by ELISA.
** = p < 0.01 compared to non-stimulated control (n = 6). (C) Sustained knockdown of MALAT1 expression in OA osteoblasts
over 21 days following repeated transfection with a MALAT1 LNA or control LNA. * = p < 0.05, *** = p < 0.001 compared to
non-stimulated control (n = 6). (D) Production of OPG (pg/mL) over 21 days in control LNA and MALAT1 LNA transfected
OA osteoblasts (n = 6) as determined by ELISA. (E) Alkaline phosphatase (ALP) activity over 21 days in control LNA and
MALAT1 LNA transfected OA osteoblast lysates (n = 6). (F) Relative amount of osteoblast mineralisation following 21 days
of transfection with control (NC) or MALAT1 (M1) LNA as determined quantification of absorbance at following alizarin
red staining, and representative light microscope images (×40 magnification) showing alizarin red stained mineralised
bone nodules.
4. Discussion
This paper reports the expression and functional role of the long non-coding RNA
MALAT1 in OA patient subchondral bone tissue and primary OA osteoblasts. MALAT1
was found to be highly expressed (compared to non-OA hip) in the subchondral bone
tissue of both knee and hip OA patients irrespective of disease severity. On average
MALAT1 expression was greater in the bone tissue from patients with greater OA severity,
as measured by either KL grade or joint space narrowing. However, it should be noted
that all the OA patients in this study had advanced end-stage disease, with radiographic
severity determined to be either KL3 or KL4, and most patients having <1 mm joint space.
Therefore, we cannot comment on whether expression of MALAT1 would differ in the
subchondral bone of patients with early OA.
Similar to previous findings on the role of MALAT1 in OA synovial fibroblasts [23],
MALAT1 expression in OA osteoblasts was induced during the IL-1β inflammatory re-
sponse. This suggests MALAT1 may play an important regulatory role in bone homeostasis
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under the inflammatory conditions exhibited in OA patients. Of note, although the sub-
chondral bone expression of MALAT1 was not related to the serum concentration of IL-1β
we did observe positive correlations between MALAT1 expression and the serum concentra-
tion of both DKK1 and galectin 1. DKK1 is an endogenous inhibitor of the Wnt/beta-catenin
signalling pathway and is implicated in bone development and in the pathological remod-
elling of bone in both OA and osteoporosis and mediating inflammation-induced bone
loss by inhibiting osteoblast differentiation [30,31]. In osteoporosis patients, serum levels
of DKK1 are negatively associated with bone mineral density in the femoral head and
lumbar spine [32]. In contrast, galectin-1 has been identified as secreted protein which
promotes osteoblast differentiation [33], and in mediating osteoclast activity in osteolytic
bone disease [34].
LNA-mediated knockdown of MALAT1 in primary human OA osteoblasts profoundly
affected the transcriptomic phenotype with pathway analysis revealing significant ac-
tivation of pathways that promote the production of inflammatory prostacyclins and
eicosanoids. Amongst the most differentially expressed upregulated genes were TNFSF12
(>11-fold upregulated), which encodes TWEAK (TNF-related weak inducer of apoptosis).
TWEAK is a known mediator of inflammatory bone remodelling [35], and targeted inhibi-
tion of the TWEAK/fibroblast growth factor inducible 14 (FnF14) signalling pathway has
been proposed as a therapeutic strategy to reduce bone resorption in rheumatoid arthritis
patients [36]. In addition, osteoblasts depleted of MALAT1 exhibited a significant >10-fold
upregulation in the expression of PTGS2, the gene which encodes for the enzyme COX2
that mediates the production of inflammatory prostaglandins including the putative OA
pain mediator PGE2 [37,38]. Indeed, we found that both basal and IL-1β induced PGE2
secretion was significantly greater in osteoblasts depleted of MALAT1 compared to control
cells. PGE2 acting through the E prostanoid receptors EP2 and EP4 sensitizes nociceptors,
possibly by acting synergistically with IL1β to induce IL-6 and iNOS expression [39] and
selective COX2 inhibitors such as celecoxib are known to reduce pain and inflammation
in OA patients [40]. The subchondral bone is considered to be an important site of OA
pain, being innervated with sensory neurones [41] and bone marrow lesions (identified as
hyper-intense regions on T1-weighted MRI scans) and bone shape in OA patients being
associated with bone pain [42]. Therefore, our finding here that MALAT1 expression in
OA osteoblasts regulates PTGS2 expression as well as both basal and IL-1β induced PGE2
production suggests that MALAT1 may play an important role in regulating inflammatory
pain in the bone.
Despite the effect of MALAT1 knockdown on the osteoblast transcriptome and the
acute effect on PGE2 production we did not observe any chronic effect of MALAT1 knock-
down on several key osteoblast functions. During a time-period of 3 weeks, we induced
sustained MALAT1 knockdown but did not observe any significant difference in the secre-
tion of OPG or in the activity of ALP and ability of the osteoblast to form mineralised bone
nodules. This contrasts with previous publications which have implicated MALAT1 in me-
diating both OPG production in osteoblasts [43] as well as ALP activity and mineralisation
during osteoblast differentiation [44].
The underlining molecular mechanisms by which lncRNAs mediate their function
is complex and for the majority of lncRNAs remains to be determined. Several lncRNAs,
including MALAT1 have been reported to exert a pro-osteogenic function by acting as
miRNA sponges [45]. Indeed, the reported role for MALAT1 in mediating osteoblast
differentiation has been linked to the sponging of several miRNAs including miR-204 [45],
miR-30 [26] and miR-43 [46]. In our analysis of the OA osteoblast transcriptome analysis
following MALAT1 depletion, we did not identify any miRNAs which were altered upon
MALAT1 KD. However, the isolation of total RNA using columns would likely have
excluded many miRNAs from our sequencing analysis.
Cells 2021, 10, 786 10 of 12
5. Conclusions
In conclusion, the expression of MALTA1 in OA subchondral bone, its induction
in osteoblasts upon inflammatory challenge and its functional role in modulating the
production of the prostaglandin PGE2 suggest that MALAT1 may play an important role in
the development of OA bone pain and inflammation.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/cells10040786/s1, Table S1: MALAT1 and joint severity, Table S2: RNAseq All DEGs, Table S3:
RNAseq Common DEGs.
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